Thursday May 25th 2017

‘Tech’ Archives

Prof. Dake’s presentation on CCSVI part 1

Prof. Dake’s presentation on CCSVI part 1

Prof. Dake gives a presentation at the annual meeting of interventional radiologists about stenting jugular veins for MS. The presentations can be watched on a webcast: hosted.mediasite.com Posted by Sam Daniels [Read More]

CCSVI As Cause of Multiple Sclerosis

CCSVI As Cause of Multiple Sclerosis

Images from my diagnostic MRV showing jugular stenosis, and corrective stents/angioplasty. More at healingpowernow.com Posted by Mark [Read More]

Helen Yates of MSRC discusses MS & CCSVI

Helen Yates of MSRC discusses MS & CCSVI

Helen Yates, Chief Executive of MSRC discusses MS and Chronic Cerebrospinal Venous Insufficiency – CCSVI on BBC Radio Essex. Posted by Harris Luis [Read More]

 Page 1 of 5  1  2  3  4  5 »

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]